Bertrand Tombal

30.4k total citations · 10 hit papers
459 papers, 14.2k citations indexed

About

Bertrand Tombal is a scholar working on Pulmonary and Respiratory Medicine, Radiology, Nuclear Medicine and Imaging and Oncology. According to data from OpenAlex, Bertrand Tombal has authored 459 papers receiving a total of 14.2k indexed citations (citations by other indexed papers that have themselves been cited), including 389 papers in Pulmonary and Respiratory Medicine, 149 papers in Radiology, Nuclear Medicine and Imaging and 121 papers in Oncology. Recurrent topics in Bertrand Tombal's work include Prostate Cancer Treatment and Research (363 papers), Prostate Cancer Diagnosis and Treatment (161 papers) and Radiopharmaceutical Chemistry and Applications (126 papers). Bertrand Tombal is often cited by papers focused on Prostate Cancer Treatment and Research (363 papers), Prostate Cancer Diagnosis and Treatment (161 papers) and Radiopharmaceutical Chemistry and Applications (126 papers). Bertrand Tombal collaborates with scholars based in Belgium, United States and France. Bertrand Tombal's co-authors include Karim Fizazi, Frédéric Lecouvet, Cora N. Sternberg, Laurence Collette, Hendrik Van Poppel, Kurt Miller, Fred Saad, Axel Heidenreich, Neal D. Shore and Piet Ost and has published in prestigious journals such as New England Journal of Medicine, The Lancet and Journal of Biological Chemistry.

In The Last Decade

Bertrand Tombal

431 papers receiving 14.0k citations

Hit Papers

Characterisation and clas... 2010 2026 2015 2020 2020 2020 2012 2010 2014 200 400 600
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Characterisation and classification of oligometastatic disease: a European Society for Radiotherapy and Oncology and European Organisation for Research and Treatment of Cancer consensus recommendation
    2020 631 citations Yolande Lievens, Laurence Collette et al. The Lancet Oncology profile →
  2. Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
    2020 577 citations Karim Fizazi, Piet Ost et al. Annals of Oncology profile →
  3. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911)
    2012 560 citations Hendrik Van Poppel, Bertrand Tombal et al. profile →
  4. Magnetic Resonance Imaging for the Detection, Localisation, and Characterisation of Prostate Cancer: Recommendations from a European Consensus Meeting
    2010 555 citations Bertrand Tombal et al. European Urology profile →
  5. Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them
    2014 551 citations Paul L. Nguyen, Anthony V. D’Amico et al. European Urology profile →
  6. Cabazitaxel versus Abiraterone or Enzalutamide in Metastatic Prostate Cancer
    2019 377 citations Johann S. de Bono, Cora N. Sternberg et al. profile →
  7. Comparison of Immediate vs Deferred Cytoreductive Nephrectomy in Patients With Synchronous Metastatic Renal Cell Carcinoma Receiving Sunitinib
    2018 306 citations Igle J. de Jong, Bertrand Tombal et al. JAMA Oncology profile →
  8. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer
    2020 259 citations Neal D. Shore, Fred Saad et al. profile →
  9. Metastasis-Free Survival Is a Strong Surrogate of Overall Survival in Localized Prostate Cancer
    2017 251 citations Wanling Xie, Marc Buyse et al. Journal of Clinical Oncology profile →
  10. Darolutamide Plus Androgen-Deprivation Therapy and Docetaxel in Metastatic Hormone-Sensitive Prostate Cancer by Disease Volume and Risk Subgroups in the Phase III ARASENS Trial
    2023 99 citations Maha Hussain, Bertrand Tombal et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Bertrand Tombal Belgium 60 10.9k 3.4k 3.2k 2.6k 1.8k 459 14.2k
Kurt Miller Germany 59 9.1k 0.8× 2.7k 0.8× 2.9k 0.9× 3.5k 1.4× 4.6k 2.5× 358 14.7k
Chris Parker United Kingdom 48 8.5k 0.8× 3.3k 1.0× 2.5k 0.8× 1.7k 0.7× 1.6k 0.9× 245 11.2k
Steven Joniau Belgium 59 14.5k 1.3× 3.0k 0.9× 2.9k 0.9× 2.8k 1.1× 3.1k 1.7× 458 18.7k
Leonard G. Gomella United States 63 6.7k 0.6× 1.2k 0.3× 2.5k 0.8× 2.5k 1.0× 3.4k 1.9× 385 12.7k
Judd W. Moul United States 77 14.6k 1.3× 1.5k 0.4× 3.9k 1.2× 3.2k 1.3× 3.9k 2.1× 526 20.5k
Tomasz M. Beer United States 59 10.8k 1.0× 3.6k 1.1× 6.1k 1.9× 4.3k 1.7× 4.3k 2.4× 406 18.0k
David G. Pfister United States 69 7.2k 0.7× 2.2k 0.6× 8.9k 2.8× 1.9k 0.7× 2.8k 1.5× 328 19.3k
Misop Han United States 50 9.9k 0.9× 1.0k 0.3× 1.7k 0.5× 1.7k 0.7× 1.7k 0.9× 225 12.1k
David G. McLeod United States 61 9.7k 0.9× 754 0.2× 2.5k 0.8× 2.4k 0.9× 3.0k 1.7× 271 13.3k
Mario A. Eisenberger United States 74 21.3k 2.0× 6.1k 1.8× 8.5k 2.6× 6.4k 2.5× 5.1k 2.8× 380 27.2k

Countries citing papers authored by Bertrand Tombal

Since Specialization
Citations

This map shows the geographic impact of Bertrand Tombal's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bertrand Tombal with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bertrand Tombal more than expected).

Fields of papers citing papers by Bertrand Tombal

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bertrand Tombal. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bertrand Tombal. The network helps show where Bertrand Tombal may publish in the future.

Co-authorship network of co-authors of Bertrand Tombal

This figure shows the co-authorship network connecting the top 25 collaborators of Bertrand Tombal. A scholar is included among the top collaborators of Bertrand Tombal based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Bertrand Tombal. Bertrand Tombal is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Ravi, Praful, Wanling Xie, Silke Gillessen, et al.. (2025). Evaluation of clinical risk stratification to determine benefit from long-term versus short-term androgen deprivation in high-risk localized prostate cancer. Prostate Cancer and Prostatic Diseases. 29(1). 202–204. 1 indexed citations
2.
Azad, Arun, Louise Kostos, Gerhardt Attard, et al.. (2025). Combination Therapies in Locally Advanced and Metastatic Hormone-sensitive Prostate Cancer. European Urology. 87(4). 455–467. 5 indexed citations
3.
Roubaud, Guilhem, Marie Kostine, Ray McDermott, et al.. (2025). Assessment of bone mineral density in men with de novo metastatic castration-sensitive prostate cancer treated with or without abiraterone acetate plus prednisone in the PEACE-1 phase 3 trial. European Journal of Cancer. 218. 115293–115293. 2 indexed citations
4.
5.
6.
Ravi, Praful, Wanling Xie, Marc Buyse, et al.. (2024). Refining Risk Stratification of High-risk and Locoregional Prostate Cancer: A Pooled Analysis of Randomized Trials. European Urology. 87(2). 217–224. 2 indexed citations
7.
Spratt, Daniel E., Daniel J. George, Neal D. Shore, et al.. (2024). Efficacy and Safety of Radiotherapy Plus Relugolix in Men With Localized or Advanced Prostate Cancer. JAMA Oncology. 10(5). 594–594. 4 indexed citations
8.
9.
10.
Cowan, Bruce, et al.. (2023). Treatment-Related Cognitive Impairment in Patients with Prostate Cancer: Patients’ Real-World Insights for Optimizing Outcomes. Advances in Therapy. 41(2). 476–491. 3 indexed citations
11.
Nelson, Adam J., Renato D. Lópes, Hwanhee Hong, et al.. (2023). Cardiovascular Effects of GnRH Antagonists Compared With Agonists in Prostate Cancer. JACC CardioOncology. 5(5). 613–624. 18 indexed citations
12.
Wang, Shanshan, Cheng Fu, Qing Zou, et al.. (2023). Efficacy and safety of darolutamide in Chinese patients with metastatic hormone-sensitive prostate cancer (mHSPC): A subpopulation analysis of the phase 3 ARASENS study.. Journal of Clinical Oncology. 41(16_suppl). e17076–e17076. 1 indexed citations
13.
Joshua, Anthony M., Andrew J. Armstrong, Megan Crumbaker, et al.. (2022). Statin and metformin use and outcomes in patients with castration-resistant prostate cancer treated with enzalutamide: A meta-analysis of AFFIRM, PREVAIL and PROSPER. European Journal of Cancer. 170. 285–295. 21 indexed citations
14.
Capitanio, Umberto, Riccardo Autorino, Marco Bandini, et al.. (2021). Incidental Prostate Cancer (cT1a–cT1b) Is a Relevant Clinical and Research Entity and Should Be Fully Discussed in the International Prostate Cancer Guidelines. European Urology Oncology. 5(2). 256–258. 10 indexed citations
15.
Lecouvet, Frédéric, Daniela E. Oprea‐Lager, Yan Liu, et al.. (2018). Use of modern imaging methods to facilitate trials of metastasis-directed therapy for oligometastatic disease in prostate cancer: a consensus recommendation from the EORTC Imaging Group. The Lancet Oncology. 19(10). e534–e545. 87 indexed citations
16.
Body, Jean‐Jacques, Evangelos Terpos, Bertrand Tombal, et al.. (2016). Bone health in the elderly cancer patient: A SIOG position paper. Cancer Treatment Reviews. 51. 46–53. 33 indexed citations
17.
Fossati, Nicola, R. Jeffrey Karnes, C. Cozzarini, et al.. (2015). Assessing the Optimal Timing for Early Salvage Radiation Therapy in Patients with Prostate-specific Antigen Rise After Radical Prostatectomy. European Urology. 69(4). 728–733. 73 indexed citations
18.
19.
Tombal, Bertrand, Peter Iversen, Hendrik Van Poppel, et al.. (2006). Determining the dose of degarelix for effective therapy of prostate cancer patients as investigated by the degarelix study groups. Annals of Oncology. 17. 150–150. 2 indexed citations
20.
Cosyns, Jean‐Pierre, et al.. (2005). Malacoplalakie chez l'enfant.. Progrès en Urologie. 15(3). 511–513. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Kurt Miller Breakdown of academic impact, for papers by Chris Parker Breakdown of academic impact, for papers by Steven Joniau Breakdown of academic impact, for papers by Leonard G. Gomella Breakdown of academic impact, for papers by Judd W. Moul Breakdown of academic impact, for papers by Tomasz M. Beer Breakdown of academic impact, for papers by David G. Pfister Breakdown of academic impact, for papers by Misop Han Breakdown of academic impact, for papers by David G. McLeod Breakdown of academic impact, for papers by Mario A. Eisenberger
Rankless by CCL
2026